ETFs Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 07:08:40 12/05/2026 pm IST			5-day change	1st Jan Change
1,699.75 ^DKK	+2.46%		-3.40%	-17.27%

12:05pm	Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target	FW
11/05	Deutsche Bank trims Genmab price target to DKK 2,250 (2,400), reiterates Buy	FW

ETFs positioned on Genmab A/S

Name	Varia. Jan 1.	Weight	AuM
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	+5.07%	0.75%	27 M€
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF	+3.71%	0.11%	33,076 M€
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	+7.36%	0.04%	426 M€
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	+3.14%	0.02%	37 M€
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR	+1.19%	0.01%	15 M€
CI MARRET ALTERNATIVE ABSOLUTE RETURN BOND ETF - CAD	0.00%	-0%	12 M€

1 2

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).

Employees

3,088

Sector

Biotechnology & Medical Research

Calendar

06/08 - Earnings release - Q2 2026

More about the company